Liberta RC™ deep brain stimulation (DBS) system, recently approved by the U.S. FDA, features NeuroSphere™ Virtual Clinic, which allows for remote programming of the system System offers the longest ...

Abbott Laboratories (NYSE:ABT) received FDA approval to launch the Liberta RC DBS system, the world’s smallest rechargeable deep brain stimulation (DBS) device with remote programming, to treat people ...

Abbott’s Infinity Deep Brain Stimulation (DBS) system has received an expanded clearance from the FDA that now permits the targeted stimulation of a new area of the brain associated with Parkinson’s ...

Credit: Abbott. Liberta RC DBS is the smallest rechargeable DBS device featuring the NeuroSphere Virtual Clinical, which allows for remote programming capabilities. The Food and Drug Administration ...

Abbott has received U.S. Food & Drug Administration approval to launch a deep brain stimulation system (DBS) that the company touts as the world's smallest rechargeable device of its kind, the medical ...

The U.S. FDA granted Abbott Breakthrough Device designation to explore deep brain stimulation (DBS) for treatment-resistant depression (TRD) as an option to improve the lives of people with this ...

Abbott Laboratories is launching a clinical trial applying its deep brain stimulation system to a tough-to-treat form of depression. The company called its "Transcend" study a pivotal trial for ...